The U.S. Patent and Trademark Office (USPTO) ruled in an interference proceeding yesterday that The Broad Institute, Inc., Massachusetts Institute of Technology, and President and Fellows of Harvard College (“Broad”) have priority over The Regents of the University of California, University of Vienna, and Emmanuelle Charpentier (“CVC”) with respect to who was first to invent the use of single-guide CRISPR-Cas9 genome engineering technology in eukaryotic cells.
Patent
- Enablement
- Fee Shifting
- Litigation
- Other Barks & Bites for Friday, February 3: Trump Sues for Copyright Infringement, Google Wins Transfer from TX to CA, and Nike Takes Lululemon to Court for Patent Infringement
- Revolution Rope Inventor Tells Justices She Deserves Her Day in Article III Court
- The USPTO Claims it Wants to Ensure ‘Robust and Reliable’ Patents – But Its Questions Imply Another Assault on Patent Owners
- USPTO Issues Final Rule to Eliminate CLE Certification Program
- This Week in Washington IP: IPWatchdog Event to Review the State of the PTAB; US Inventor Protests in D.C.; and the House Considers Supply Chain Challenges
Recent Posts
- Other Barks & Bites for Friday, February 3: Trump Sues for Copyright Infringement, Google Wins Transfer from TX to CA, and Nike Takes Lululemon to Court for Patent Infringement
- Revolution Rope Inventor Tells Justices She Deserves Her Day in Article III Court
- The USPTO Claims it Wants to Ensure ‘Robust and Reliable’ Patents – But Its Questions Imply Another Assault on Patent Owners
- USPTO Issues Final Rule to Eliminate CLE Certification Program
- This Week in Washington IP: IPWatchdog Event to Review the State of the PTAB; US Inventor Protests in D.C.; and the House Considers Supply Chain Challenges